麻州丹弗斯, Oct. 27, 2017 (GLOBE NEWSWIRE) -- 一流的劃時代心臟支架技術供應商Abiomed, Inc. (NASDAQ:ABMD) 今天宣佈,2018財政年度第2季度營收1.328億美元,較2017財政年度同期營收1.03億美元增長29%。2018財政年度第2季度的GAAP淨利為2,450萬美元,攤薄後每股獲利0.54美元,而去年同期的GAAP淨利為890萬美元,攤薄後每股獲利0.20美元。
2018財政年度第2季度的財務和經營亮點包括:
- 來自Impella心臟泵的全球營收總計為1.274億美元,較上個財政年度同期營收9,790萬美元增長30%。來自Impella心臟泵的美國營收增長27%,為1.136億美元;在美國,Impella的病患者使用率亦增長33%。
- 在美國境外,Impella心臟泵的營收總計為1,380萬美元,增長61%,其中主要來自德國,其營收較上個財政年度增長64%,病患人數刷新紀錄。
- 在美國, Impella 2.5®心臟泵的安裝基地再增加17家首次購買Impella心臟泵的醫院,使客戶安裝的地點總數達到1,171個。Impella CP®心臟泵的客戶安裝基地新增31家美國醫院,使得安裝Impella CP的地點總數達到1,093處。Impella 5.0®心臟泵的客戶安裝基地新增12家美國醫院,使得安裝Impella 5.0的地點總數達到484處。
- 本季度另有44個安裝地點首次購買Impella RP®心臟泵,使得安裝地點總數達到186處。
- 毛利率為84%,上個財政會計年度為83%。
- 營業營收為3,170萬美元,營業毛利為24%,去年的營業營收為1,450萬美元,營業毛利率為14%。
- 受益於採用新會計準則,GAAP淨利為2,450萬美元,攤薄後每股獲利0.54美元;根據新會計準則,一項金額450萬美元、攤薄後每股獲利0.10美元的員工股票薪酬相關獎勵應認列為所得稅抵減項,因此有溢收稅額。去年,採納新會計準則之前的GAAP淨利為890萬美元,攤薄後每股獲利0.20美元。
- 本公司創造3,010萬美元的現金、現金等價物及有價證券,截至2017年9月30日的總額為3.192億美元,而2017年6月30日則為2.891億美元。本公司目前沒有負債。
- 2017年9月20日,Abiomed 的Impella RP心臟泵獲得美國食品藥物管理局 (FDA) 上市前核准 (PMA)。通過審核後,Impella RP 心臟泵成為唯一獲得 FDA 核可具安全性和有效性的經皮暫時性心室支援裝置,用於治療右心衰竭。
- 在今天另一份新聞稿中,Abiomed宣佈日本已有首名病患者接受Impella®心臟泵的治療。Impella 2.5和Impella 5.0心臟泵獲許可用於治療耐藥性的急性心臟衰竭,且是日本醫藥品醫療機器綜合機構 (PMDA) 核可的第一個且唯一一個經皮暫時性心室支援裝置。
Abiomed董事長、總裁兼執行長Michael R. Minogue表示:「本季度,我們在幫助美國和德國的病患者方面刷新了記錄,且我們繼續看到教育和培訓計劃創造出更佳的臨床結果。團隊不斷適應並持續執行的能力讓我感到自豪,我們改革了護理標準,更打造了心臟復原領域的一片天。」
2018財政年度展望
本公司將2018財政年度營收財測的下限再度上調500萬美元,新範圍為5.65億美元至5.75億美元,較去年的營收增長27%至29%。之前的預測值為5.55億美元至5.75億美元,較去年增長25%至29%。本公司亦上調本財政年度GAAP營業毛利率的預測值,從22%至24%調升至23%至25%。
視訊會議
公司將於2017年10月26日星期四美國東部夏令時間早上8:00舉行視訊會議以討論業績。董事長、總裁兼執行長Michael R. Minogue、前財務長Robert L. Bowen將主持視訊會議。
欲收聽視訊會議直播,請透過http://investor.abiomed.com打開網路直播或撥打(855) 212-2361,國際號碼為(678) 809-1538。本次視訊會議將在2017年10月26日美國東部夏令時間上午11點至2017年10月29日美國東部夏令時間上午11點重播。重播電話號碼為(855) 859-2056,國際號碼為(404) 537-3406。重播接入碼為95924236。
ABIOMED 標識、ABIOMED、Impella、Impella CP和Impella RP為Abiomed, Inc.在美國及若干其他國家註冊的商標。Impella 2.5、Impella 5.0、Impella LD和Recovering Hearts、Saving Lives為Abiomed, Inc.的商標。
關於ABIOMED
Abiomed, Inc. 的總部設在美國麻州丹佛斯市,是一家一流的循環支援醫療器械的供應商。我們的產品用於改善血液流動及/或執行心臟的泵血功能,從而讓心臟得以休息。欲瞭解更多資訊,請瀏覽網站:www.abiomed.com。
前瞻性聲明
本新聞稿包含前瞻性聲明,包括有關 Abiomed 現有產品及新產品的開發、本公司的商業發展進度、未來機會以及預期監管審核的陳述。本公司的實際業績可能與前瞻性聲明中所預計的業績存在重大差異,其原因很多,包括開發、測試及相關監管審核所存在的不確定性,其中包括未來可能虧損、製造工藝複雜、品質要求高、對有限供貨來源的依賴、競爭、技術變革、政府監管、訴訟事務、未來資本需求、後續融資的不確定性以及本公司在向美國證券交易委員會報備的文件中詳細描述的其他風險及挑戰,其中包括最近提報的10-K年度報表以及以10-Q季度報表。讀者應謹慎,不應不當仰賴任何前瞻性聲明,該等陳述僅反映截至本新聞稿發佈之日的情況。本公司並無義務公開發佈任何前瞻性陳述之修正,以因應本新聞稿發佈之日後發生的事件或情況或反映意外事件之發生。
Abiomed, Inc. and Subsidiaries | |||||||||
Consolidated Balance Sheets | |||||||||
(Unaudited) | |||||||||
(in thousands, except share data) | |||||||||
September 30, 2017 | March 31, 2017 | ||||||||
ASSETS | |||||||||
Current assets: | |||||||||
Cash and cash equivalents | $ | 44,536 | $ | 39,040 | |||||
Short-term marketable securities | 218,661 | 190,908 | |||||||
Accounts receivable, net | 57,327 | 54,055 | |||||||
Inventories | 40,632 | 34,931 | |||||||
Prepaid expenses and other current assets | 9,014 | 8,024 | |||||||
Total current assets | 370,170 | 326,958 | |||||||
Long-term marketable securities | 55,954 | 47,143 | |||||||
Property and equipment, net | 97,697 | 87,777 | |||||||
Goodwill | 34,332 | 31,045 | |||||||
In-process research and development | 16,016 | 14,482 | |||||||
Long-term deferred tax assets, net | 106,798 | 34,723 | |||||||
Other assets | 13,686 | 8,286 | |||||||
Total assets | $ | 694,653 | $ | 550,414 | |||||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||
Current liabilities: | |||||||||
Accounts payable | $ | 16,667 | $ | 20,620 | |||||
Accrued expenses | 35,256 | 37,703 | |||||||
Deferred revenue | 10,584 | 10,495 | |||||||
Current portion of capital lease obligation | 851 | 799 | |||||||
Total current liabilities | 63,358 | 69,617 | |||||||
Other long-term liabilities | 598 | 3,251 | |||||||
Contingent consideration | 9,835 | 9,153 | |||||||
Long-term deferred tax liabilities | 866 | 783 | |||||||
Capital lease obligation, net of current portion | 15,110 | 15,539 | |||||||
Total liabilities | 89,767 | 98,343 | |||||||
Commitments and contingencies | |||||||||
Stockholders' equity: | |||||||||
Class B Preferred Stock, $.01 par value | — | — | |||||||
Authorized - 1,000,000 shares; Issued and outstanding - none | |||||||||
Common stock, $.01 par value | 442 | 437 | |||||||
Authorized - 100,000,000 shares; Issued - 45,921,029 shares at September 30, 2017 and 45,249,281 shares at March 31, 2017 | |||||||||
Outstanding - 44,200,784 shares at September 30, 2017 and 43,673,286 shares at March 31, 2017 | |||||||||
Additional paid in capital | 592,081 | 565,962 | |||||||
Retained earnings (accumulated deficit) | 90,164 | (46,959 | ) | ||||||
Treasury stock at cost - 1,720,245 shares at September 30, 2017 and 1,575,995 shares at March 31, 2017 | (65,999 | ) | (46,763 | ) | |||||
Accumulated other comprehensive loss | (11,802 | ) | (20,606 | ) | |||||
Total stockholders' equity | 604,886 | 452,071 | |||||||
Total liabilities and stockholders' equity | $ | 694,653 | $ | 550,414 | |||||
Abiomed, Inc. and Subsidiaries | ||||||||||||||
Consolidated Statements of Operations | ||||||||||||||
(Unaudited) | ||||||||||||||
(in thousands, except per share data) | ||||||||||||||
Three Months Ended September 30, | Six Months Ended September 30, | |||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||
Revenue: | ||||||||||||||
Product revenue | $ | 132,782 | $ | 102,928 | $ | 265,213 | $ | 205,917 | ||||||
Funded research and development | 41 | 27 | 78 | 33 | ||||||||||
132,823 | 102,955 | 265,291 | 205,950 | |||||||||||
Costs and expenses: | ||||||||||||||
Cost of product revenue | 21,627 | 17,309 | 43,489 | 32,379 | ||||||||||
Research and development | 19,390 | 18,052 | 36,321 | 33,712 | ||||||||||
Selling, general and administrative | 60,080 | 53,086 | 120,677 | 104,118 | ||||||||||
101,097 | 88,447 | 200,487 | 170,209 | |||||||||||
Income from operations | 31,726 | 14,508 | 64,804 | 35,741 | ||||||||||
Other income: | ||||||||||||||
Investment income, net | 781 | 342 | 1,416 | 611 | ||||||||||
Other (expense) income, net | (23 | ) | (114 | ) | 56 | (191 | ) | |||||||
758 | 228 | 1,472 | 420 | |||||||||||
Income before income taxes | 32,484 | 14,736 | 66,276 | 36,161 | ||||||||||
Income tax provision (1) | 7,981 | 5,861 | 4,399 | 14,376 | ||||||||||
Net income | $ | 24,503 | $ | 8,875 | $ | 61,877 | $ | 21,785 | ||||||
Basic net income per share | $ | 0.56 | $ | 0.21 | $ | 1.41 | $ | 0.51 | ||||||
Basic weighted average shares outstanding | 44,141 | 43,129 | 44,018 | 42,971 | ||||||||||
Diluted net income per share (2) | $ | 0.54 | $ | 0.20 | $ | 1.36 | $ | 0.49 | ||||||
Diluted weighted average shares outstanding | 45,698 | 44,580 | 45,655 | 44,493 | ||||||||||
(1) Income tax provision includes the effect of the following item: | ||||||||||||||
Excess tax benefits related to stock-based compensation awards * | $ | 4,434 | $ | — | $ | 21,276 | $ | — | ||||||
(2) Diluted net income per share includes the effect of the following item: | ||||||||||||||
Excess tax benefits related to stock-based compensation awards * | $ | 0.10 | $ | — | $ | 0.47 | $ | — | ||||||
* In the first quarter of fiscal 2018, the Company adopted Accounting Standards Update No. 2016-09, Improvements to Employee Share-Based Payment Accounting, which requires that all excess tax benefits and tax deficiencies related share-based compensation arrangements be recognized as income tax benefit or expense, instead of in stockholders' equity as previous guidance required. |
欲瞭解更多資訊,請聯絡:
Ingrid Goldberg,
投資者關係部總監
978-646-1590
ir@abiomed.com